drugset / Trial / NCT06792344

Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

NCT06792344

NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset systemic sclerosis

Timeline

Start
2024-12-15
Primary completion
2027-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CD19 CAR-T cells Cell therapy Intravenous

Indications